Home>Homework Answsers>Nursing homework helpurgentPLEASE FOLLOW THE INSTRUCTIONS AS INDICATED BELOW1). ZERO (0) PLAGIARISM2). ATLEAST 5 REFERENCES, NO MORE THAN 5 YEARS3). PLEASE SEE ATTACHED RUBRIC DETAILS AND RECOMMENDED COURSE WRITING TEMPLATE AND APA 7 STYLE4). Please review and follow the grading rubric details, and include each component in the assignment as required. Also, follow the APA writing rules and style, Title page, summary, Purpose statement, Conclusion.For your Assignment, your Instructor will assign you one of the decision tree interactive media pieces provided in the Resources. As you examine the patient case studies in this module’s Resources, consider how you might assess and treat patients presenting symptoms of neurological and musculoskeletal disorders.To PrepareReview the interactive media piece assigned.Reflect on the patient’s symptoms and aspects of the disorder presented in the interactive media piece.Consider how you might assess and treat patients presenting with the symptoms of the patient case study you were assigned.You will be asked to make three decisions concerning the diagnosis and treatment for this patient. Reflect on potential co-morbid physical as well as patient factors that might impact the patient’s diagnosis and treatment.Write a 1- to 2-page summary paper that addresses the following:Briefly summarize the patient case study you were assigned, including each of the three decisions you took for the patient presented.Based on the decisions you recommended for the patient case study, explain whether you believe the decisions provided were supported by the evidence-based literature. Be specific and provide examples. Be sure to support your response with evidence and references from outside resources.What were you hoping to achieve with the decisions you recommended for the patient case study you were assigned? Support your response with evidence and references from outside resources.Explain any difference between what you expected to achieve with each of the decisions and the results of the decision in the exercise. Describe whether they were different. Be specific and provide examples.Alzheimer’s Disease76-year-old Iranian MaleBACKGROUNDMr. Akkad is a 76 year old Iranian male who is brought to your office by his eldest son for “strange behavior.” Mr. Akkad was seen by his family physician who ruled out any organic basis for Mr. Akkad’s behavior. All laboratory and diagnostic imaging tests (including CT-scan of the head) were normal.According to his son, he has been demonstrating some strange thoughts and behaviors for the past two years, but things seem to be getting worse. Per the client’s son, the family noticed that Mr. Akkad’s personality began to change a few years ago. He began to lose interest in religious activities with the family and became more “critical” of everyone. They also noticed that things he used to take seriously had become a source of “amusement” and “ridicule.”Over the course of the past two years, the family has noticed that Mr. Akkad has been forgetting things. His son also reports that sometimes he has difficult “finding the right words” in a conversation and then will shift to an entirely different line of conversation.SUBJECTIVEDuring the clinical interview, Mr. Akkad is pleasant, cooperative and seems to enjoy speaking with you. You notice some confabulation during various aspects of memory testing, so you perform a Mini-Mental State Exam. Mr. Akkad scores 18 out of 30 with primary deficits in orientation, registration, attention & calculation, and recall. The score suggests moderate dementia.MENTAL STATUS EXAMMr. Akkad is 76 year old Iranian male who is cooperative with today’s clinical interview. His eye contact is poor. Speech is clear, coherent, but tangential at times. He makes no unusual motor movements and demonstrates no tic. Self-reported mood is euthymic. Affect however is restricted. He denies visual or auditory hallucinations. No delusional or paranoid thought processes noted. He is alert and oriented to person, partially oriented to place, but is disoriented to time and event [he reports that he thought he was coming to lunch but “wound up here”- referring to your office, at which point he begins to laugh]. Insight and judgment are impaired. Impulse control is also impaired as evidenced by Mr. Akkad’s standing up during the clinical interview and walking towards the door. When you asked where he was going, he stated that he did not know. Mr. Akkad denies suicidal or homicidal ideation.Diagnosis: Major neurocognitive disorder due to Alzheimer’s disease (presumptive)RESOURCES§ Folstein, M. F., Folstein, S. E., & McHugh, P. R. (2002). Mini-Mental State Examination (MMSE). Lutz, FL: Psychological Assessment Resources.Decision Point OneSelect what you should do:Decision Point OneBegin Exelon (rivastigmine) 1.5 mg orally BID with an increase to 3 mg orally BID in 2 weeksRESULTS OF DECISION POINT ONEClient returns to clinic in four weeksThe client is accompanied by his son who reports that his father is “no better” from this medication. He reports that his father is still disinterested in attending religious services/activities, and continues to exhibit disinhibited behaviorsYou continue to note confabulation and decide to administer the MMSE again. Mr. Akkad again scores 18 out of 30 with primary deficits in orientation, registration, attention & calculation, and recallDecision Point One: Begin Aricept (donepezil) 5 mg orally at BEDTIMERESULTS OF DECISION POINT ONEClient returns to clinic in four weeksThe client is accompanied by his son who reports that his father is “no better” from this medicationHe reports that his father is still disinterested in attending religious services/activities, and continues to exhibit disinhibited behaviorsYou continue to note confabulation and decide to administer the MMSE again. Mr. Akkad again scores 18 out of 30 with primary deficits in orientation, registration, attention & calculation, and recallDecision Point OneBegin Razadyne (galantamine) 4 mg orally BIDRESULTS OF DECISION POINT ONEClient returns to clinic in four weeksThe client is accompanied by his son who reports that his father is “no better” from this medicationHe reports that his father is still disinterested in attending religious services/activities, and continues to exhibit disinhibited behaviorsYou continue to note confabulation and decide to administer the MMSE again. Mr. Akkad again scores 18 out of 30 with primary deficits in orientation, registration, attention & calculation, and recallDecision Point TwoSelect what you should do next:Decision Point TwoIncrease Razadyne to 24 mg extended release dailyRESULTS OF DECISION POINT TWOClient returns to clinic in four weeksThe client’s son accompanies the client to his appointment today. The client is in a wheelchair and is somewhat agitatedYou are informed by the son that his father has not taken his medication since he got out of the hospital. Apparently, about 7 days after starting the Galantamine extended release, the client began having seizures which resulted in a fall and fractured hip. The son reports that his father is agitated with everyone and is asking for help in treating his agitationDecision Point TwoDiscontinue Razadyne and begin Aricept (donepezil) 10 mg orally dailyRESULTS OF DECISION POINT TWOClient returns to clinic in four weeksThe client is accompanied by his son for today’s appointment who informs you that he stopped giving his father the mew medication because after just a few doses, his father began experiencing appetite loss, followed by nausea, diarrhea, and vomitingDecision Point TwoDiscontinue Razadyne and begin Exelon (rivastigmine) 1.5 mg orally BIDRESULTS OF DECISION POINT TWOClient returns to clinic in four weeksClient’s son reports that the client is tolerating the medication well, but is still concerned that his father is no betterHe states that his father is still not interested in attending religious services with the family, and he is still concerned that his father is still easily amused by things he once found seriousDecision Point ThreeSelect what you should do next:Decision Point ThreeIncrease Exelon to 3 mg orally BIDGuidance to StudentCholinesterase inhibitors can take months to demonstrate any stabilization in the degenerative course of Alzheimer’s disease. Since the client has had no side effects, it would be prudent to consider increasing the Exelon dose to 3 mg orally BID. Recall that the target dose of Exelon is 12 mg orally daily in divided doses, or a transdermal patch delivering 9.5 mg daily could be used. Slow titration of the drug toward a therapeutic dose will decrease the risk of side effects. These should be teaching points directed toward the client and his son.You could maintain the current dose of Exelon and reevaluate at the next office visit, but since the client is having no side effects and the client has been on the current dose for at least 4 weeks, it would probably be advisable to increase at this time to facilitate the goal of arriving at a therapeutic dose of the medication.It may be early to augment with Namenda. Maximization of the Exelon dose should first occur, then augmentation with an NMDA receptor antagonist would be appropriate, but Namenda should be started at 5 mg orally daily, and then titrated up to a maximum dose of 10 mg orally BID. Doses over 5 mg orally daily should be divided into two doses, or the drug can be switch to an extended release preparation.Finally, it is important to note that changes in the MMSE should be evaluated over the course of months, not weeks. The absence of change in the MMSE after 4 weeks of treatment should not be a source of concern.Decision Point ThreeContinue current dose of Exelon and reevaluate at next office visitGuidance to StudentCholinesterase inhibitors can take months to demonstrate any stabilization in the degenerative course of Alzheimer’s disease. Since the client has had no side effects, it would be prudent to consider increasing the Exelon dose to 3 mg orally BID. Recall that the target dose of Exelon is 12 mg orally daily in divided doses, or a transdermal patch delivering 9.5 mg daily could be used. Slow titration of the drug toward a therapeutic dose will decrease the risk of side effects. These should be teaching points directed toward the client and his son.You could maintain the current dose of Exelon and reevaluate at the next office visit, but since the client is having no side effects and the client has been on the current dose for at least 4 weeks, it would probably be advisable to increase at this time to facilitate the goal of arriving at a therapeutic dose of the medication.It may be early to augment with Namenda. Maximization of the Exelon dose should first occur, then augmentation with an NMDA receptor antagonist would be appropriate, but Namenda should be started at 5 mg orally daily, and then titrated up to a maximum dose of 10 mg orally BID. Doses over 5 mg orally daily should be divided into two doses, or the drug can be switch to an extended release preparation.Finally, it is important to note that changes in the MMSE should be evaluated over the course of months, not weeks. The absence of change in the MMSE after 4 weeks of treatment should not be a source of concern.Decision Point ThreeAugment with Namenda 10 mg orally at BEDTIMEGuidance to StudentCholinesterase inhibitors can take months to demonstrate any stabilization in the degenerative course of Alzheimer’s disease. Since the client has had no side effects, it would be prudent to consider increasing the Exelon dose to 3 mg orally BID. Recall that the target dose of Exelon is 12 mg orally daily in divided doses, or a transdermal patch delivering 9.5 mg daily could be used. Slow titration of the drug toward a therapeutic dose will decrease the risk of side effects. These should be teaching points directed toward the client and his son.You could maintain the current dose of Exelon and reevaluate at the next office visit, but since the client is having no side effects and the client has been on the current dose for at least 4 weeks, it would probably be advisable to increase at this time to facilitate the goal of arriving at a therapeutic dose of the medication.It may be early to augment with Namenda. Maximization of the Exelon dose should first occur, then augmentation with an NMDA receptor antagonist would be appropriate, but Namenda should be started at 5 mg orally daily, and then titrated up to a maximum dose of 10 mg orally BID. Doses over 5 mg orally daily should be divided into two doses, or the drug can be switch to an extended release preparation.Finally, it is important to note that changes in the MMSE should be evaluated over the course of months, not weeks. The absence of change in the MMSE after 4 weeks of treatment should not be a source of concern.ASSIGNMENTRUBRICDETAILSFORNURS6521.htmlCOURSEPAPERWRITINGTEMPLATEWITHABSTRACT-APA7.doc4 years ago22.04.202135Report issueAnswer(1)Brainy Brian4.8(904)5.0(213)ChatPurchase the answer to view itALZHEIMERSDISEASE.docxAlzheimersdisease_2.pdf4 years agoplagiarism checkPurchase $35Bids(113)Dr.Marie_MicheleDr. Ellen RMTutor Cyrus KenEmily ClareDr Michelle MayaQuickly answergrA+de plusCreative GeekDr. Adeline ZoeWIZARD_KIMQuality AssignmentsYourStudyGuruNightingaleDr. ElahiMadam MichelleBrainy BrianAmanda Smithwizard kimDr shamille ClaraRihAN_Mendozaother Questions(10)Reactions writingCivil Rights Movement in the 1960sBased on the article, “When and how provider competition can improve health care delivery,” what are the pros and cons of provider competition? Does the patient benefit, explain?Research Comair flight 5191 and review the video and other pertinent information regarding the accident. Discuss the human error in this accident and created a Causation Model to break the causefor JHON ONLYAssignment 4: Part D: Your Marketing Plan – Video Presentation Due Week 10 and worth 200 pointsPHILOSOPHY DUE IN 10 HOURSAssignmentAccounting homeworkSU FIN4055 Assignment 2-Equity Valuation, Business Plan Project, Week 5, and Comprehensive Presentation Summary
Get Answer Over WhatsApp
Order Paper Now
